Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates

Cyclacel Pharmaceuticals, Inc. (CYCC) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of$ 0.83. This compares to loss of $6.60 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 13.25%. A quarter ago, it was expected that this company would post a loss of$ 4.93 per share when it actually produced a loss of $2.27, delivering a surprise of 53.96%. Over the last four quarters, the com ...